Format

Send to

Choose Destination
Ther Clin Risk Manag. 2008 Dec;4(6):1305-13.

Tumor necrosis factor-alpha inhibitor treatment for sarcoidosis.

Author information

1
Unit of Autoimmune Systemic Diseases, Hospital Clinico San Cecilio, Granada, Spain. jlcalleja@telefonica.net

Abstract

Sarcoidosis is a chronic multisystem disease of unknown etiology, characterized by noncaseating granulomatous infiltration of virtually any organ system. Treatment is often undertaken in an attempt to resolve symptoms or prevent progression to organ failure. Previous studies have suggested a prominent role for tumor necrosis factor-alpha (TNF-alpha) in the inflammatory process seen in sarcoidosis. TNF-alpha and interleukin-1 are released by alveolar macrophages in patients with active lung disease. Corticosteroids have proved to be efficacious in the treatment of sarcoidosis, possibly by suppressing the production of TNF-alpha and other cytokines. Three agents are currently available as specific TNF antagonists: etanercept, infliximab, and adalimumab. Although data from noncomparative trials suggest that all three have comparable therapeutic effects in rheumatoid arthritis, their effects in a granulomatous disease such as sarcoidosis are less consistent. In this review, current data on the effectiveness are summarized.

KEYWORDS:

adalimumab; anti-TNA alpha; etanercept; infliximab; sarcoidosis

PMID:
19337437
PMCID:
PMC2643111

Supplemental Content

Full text links

Icon for Dove Medical Press Icon for PubMed Central
Loading ...
Support Center